The size of the Middle East and Africa sepsis diagnostics market was worth USD 35.36 Million in 2022 and USD 52.05 Million by 2027, growing at a CAGR of 8.04% from 2022 to 2027.
A few of the factors accelerating the growth of the Middle East and Africa (MEA) sepsis diagnostic market are the increased prevalence of sepsis, the increased incidence of hospital-acquired infections, the increased number of cases of pneumonia, the increased number of septic surgeries, and research activities related to sepsis. Nosocomial infections (HAIs) are the most common complication among inpatients, producing an estimated 4.5 HAIs per 100 inpatients and costing $ 35-45 billion annually. These HAIs are also called nosocomial infections. According to the Centers for Disease Control and Prevention (CDC), nosocomial infections can occur in 1 in 20 treated patients. Nosocomial infections cause more than 99,000 deaths each year. The most common causes of nosocomial diseases include surgical, respiratory, urinary tract, and bloodstream infections. Healthcare providers, nursing teams, and individual physicians and nurses are also aware of infection-related issues and have taken specific steps to prevent them. Similar hospital infections have been observed around the world, increasing the demand for sepsis diagnosis. As a result, increased nosocomial infections are supposed to drive the overall growth of the sepsis diagnostics market in the MEA over the forecast period.
However, the lack of awareness and the skilled workforce in the Middle East and Africa region are some factors that restrain the growth of the sepsis diagnostic market in the area.
One disadvantage of this approach is that it cannot identify organisms that cannot be cultured. Also, after blood culture, molecular diagnostic techniques are considered standard pathogen identification techniques.
This research report segmented and sub-segmented the Asia Pacific Sepsis Diagnostics Market into the following categories:
By Pathogen:
By Product:
By Technology:
By Method:
By Usability:
By Country:
The regional market is growing due to the growing elderly population in the region, the development of healthcare infrastructure, and increasing cancer and diabetes in countries such as UAE, Saudi Arabia, South Africa, and others. In addition, MEA Sepsis Diagnostics Market is emerging with economies that offer growth opportunities due to increased neonatal umbilical cord infections and the number of surgical procedures in this region. The newly developed test uses microelectrodes to analyze a patient's blood and achieve a final result in two and a half minutes. By developing and starting this advanced rapid test, critical players in the market have ample opportunities to strengthen their position in the local market.
KEY MARKET PLAYERS:
A few of the promising companies operating in the MEA sepsis diagnostics market profiled in the report are Biomérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pathogen
5.1.1 Introduction
5.1.2 Bacterial Sepsis
5.1.2.1 Gram-Negative Bacterial Sepsis
5.1.2.2 Gram-Positive Bacterial Sepsis
5.1.3 Fungal Sepsis
5.1.4 Other Pathogen Infections
5.1.5 Y-o-Y Growth Analysis, By Pathogen
5.1.6 Market Attractiveness Analysis, By Pathogen
5.1.7 Market Share Analysis, By Pathogen
5.2 Product
5.2.1 Introduction
5.2.2 Instruments
5.2.3 Blood Culture Media
5.2.4 Assay Kits & Reagents
5.2.5 Software
5.2.6 Y-o-Y Growth Analysis, By Product
5.2.7 Market Attractiveness Analysis, By Product
5.2.8 Market Share Analysis, By Product
5.3 Technology
5.3.1 Introduction
5.3.2 Microbiology
5.3.3 Molecular Diagnostics
5.3.4 Immunoassays
5.3.5 Flow Cytometry
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.4 Method
5.4.1 Introduction
5.4.2 Convential Diagnostics
5.4.3 Automated Diagnostics
5.4.4 Y-o-Y Growth Analysis, By Method
5.4.5 Market Attractiveness Analysis, By Method
5.4.6 Market Share Analysis, By Method
5.5 Usability
5.5.1 Introduction
5.5.2 Laboratory Testing
5.5.3 Point-of-Care Testing
5.5.4 Y-o-Y Growth Analysis, By Usability
5.5.5 Market Attractiveness Analysis, By Usability
5.5.6 Market Share Analysis, By Usability
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pathogen
6.1.3.3 By Product
6.1.3.4 By Technology
6.1.3.5 By Method
6.1.3.6 By Usability
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pathogen
6.1.4.3 By Product
6.1.4.4 By Technology
6.1.4.5 By Method
6.1.4.6 By Usability
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pathogen
6.1.5.3 By Product
6.1.5.4 By Technology
6.1.5.5 By Method
6.1.5.6 By Usability
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 bioMérieux SA
8.1.1 Overview
8.1.2 Pathogen Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 T2 Biosystem Inc
8.3 Cepheid
8.4 Thermo Fisher Scientific Inc.
8.5 Nanosphere Inc
8.6 Abbott Laboratories
8.7 Roche Diagnostics Limited
8.8 Becton, Dickinson and Company
8.9 Bruker Corporation
8.10 Beckman Coulter, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
